NGX426: Phase I started

TorreyPines began a placebo-controlled, 3-way crossover, U.S. Phase I trial to compare 90 and 150 mg doses of oral NGX426 vs. placebo in 18 healthy volunteers experiencing capsaicin-induced pain. ...